Rifampicin decreases the AUC of
imatinib by 74%. No specific studies have been carried out with
imatinib and other CYP3A4 inducers, but the manufacturers suggest that
carbamazepine will interact similarly.
The manufacturers suggest that concurrent use should be avoided. However, if this is not possible it would be prudent to monitor the outcome of concurrent use, and increase the
imatinib dose as necessary.